| Detailed information |
|---|
| CancerLivER ID | 2551 |
| Biomarker | Isocitrate dehydrogenase [NADP] (cytoplasmic), Fumarate hydratase (mitochondrial), Enoyl-CoA hydratase (mitochondrial), Betaine-homocysteine S-methyltransferase, Serotransferrin precursor |
| Biomarker Name/Symbol (given in Publication) | Isocitrate dehydrogenase [NADP] (cytoplasmic) ,Fumarate hydratase (mitochondrial), Enoyl-CoA hydratase (mitochondrial),Betaine-homocysteine S-methyltransferase, Serotransferrin precursor |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | Potential diagnostic marker for HCC; but not validated on independent dataset |
| Experimental Condition | HCC v/s non-tumor |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Downregulated in well-differentiated HCC (with 2 fold change) |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 15852300 |
| Type of Biomarker | Diagnostic |
| Pathway | metabolic pathways, Transport and binding protein |
| Cohort | Paired HCC and non-tumorous from 7 HCC patients |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | HBV-associated HCC |
| Year of Publication | 2005 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |